PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
By S. Ansell, A. Lesokhin, I. Borrello, A. Halwani, E. Scott, M. Gutierrez, S. Schuster, M. Millenson, D. Cattry, G. Freeman and 9 more. New England Journal of Medicine, 2014
3,318 citations recorded by the source corpus.
Background Preclinical studies suggest that Reed–Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1–blocking antibody, could inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma. Methods In this ongoing study, 23 patients with relapsed or refractory Hodgkin's lymphoma that had already been heavily treated received nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks until they had a complete response, tumor progression, or excessive toxic effects. Study objectives were measurement of safety and efficacy and assessment of the PDL1 and PDL2 (also called CD274 and PDCD1LG2, respectively) loci and PD-L1 and PD-L2 protein expression. Results Of the 23 study patients, 78% were enrolled in the study after a relapse following autologous stem-cell transplantation and 78% after a relapse following the receipt of brentuximab vedotin. Drug-related adverse events of any grade and of grade 3 occurred in 78% and 22% of patients, respectively. An objective response was reported in 20 patients (87%), including 17% with a complete response and 70% with a partial response; the remaining 3 patients (13%) had stable disease. The rate of progression-free survival at 24 weeks was 86%; 11 patients were continuing to participate in the study. Reasons for discontinuation included stem-cell transplantation (in 6 patients), disease progression (in 4 patients), and drug toxicity (in 2 patients). Analyses of pretreatment tumor specimens from 10 patients revealed copy-number gains in PDL1 and PDL2 and increased expression of these ligands. Reed–Sternberg cells showed nuclear positivity of phosphorylated STAT3, indicative of active JAK-STAT signaling. Conclusions Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT01592370.)
Subfields: Building and Construction, Management Science and Operations Research, Strategy and Management
View Paper: https://www.semanticscholar.org/paper/dd31cd553c2f67c596abe3085d9ad0a32586ae5e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Antoni Ribas
- Padmanee Sharma
- S. Topalian
- M. Postow
- J. Wolchok
- Kristen E. Pauken
- L. Galluzzi
- D. Pardoll
Citations in the corpus
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. (2016, background): “Sex Male 18 (58) Female 13 (42) Age, years, median (range) 32 (20 to 67) Histology Nodular sclerosis 30 (97) Mixed cellularity 1 (3) Bulky disease, $ 10 cm 2 (6) Prior brentuximab failure 31 (100) Best response to brentuximab Complete or partial response 10 (32) Stable disease 9 (29) Progressive dis”
- Management of toxicities of immune checkpoint inhibitors. (2016, background): “Anti-PD-1 antibodies such as nivolumab and pidilizumab show promise in the treatment of Hodgkin’s [24] and follicular lymphoma [25] respectively.”
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015, background): “PD-1 blockade to enhance antitumor immunity has led to durable clinical responses in patients with advanced melanoma, other solid tumors (29, 30), and Hodgkin lymphoma (31) and appears to have a favorable immune toxicity profile.”
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “In a landmark phase I study of nivolumab in a highly refractory Hodgkin lymphoma population (23 patients treated; 78% with prior autologous stem cell transplant, 78% with prior brentuximab vedotin treatment), 87% had an objective response, including 17% with complete response (32).”
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “Interestingly, recent reports suggest that the PD-1-blocking mAb nivolumab is remarkably efficient in refractory Hodgkin lymphoma (Ansell et al., 2015).”